When combined with endocrine therapy (ET), CDK4/6i enhance the effectiveness of ET and improves outcomes in hormone receptor-positive (HR+)/human epidermal growth factor receptor II-negative (HER2 −) breast cancer [2, 3]. Here, ERBB2 is linked to breast cancer.